BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7915483)

  • 1. Fumaric acid esters (FAEs) suppress CD 15- and ODP 4-positive cells in psoriasis.
    Bacharach-Buhles M; Pawlak FM; Matthes U; Joshi RK; Altmeyer P
    Acta Derm Venereol Suppl (Stockh); 1994; 186():79-82. PubMed ID: 7915483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fumaric acid esters in the management of severe psoriasis.
    Brewer L; Rogers S
    Clin Exp Dermatol; 2007 May; 32(3):246-9. PubMed ID: 17362235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulsed dye laser versus treatment with calcipotriol/betamethasone dipropionate for localized refractory plaque psoriasis: effects on T-cell infiltration, epidermal proliferation and keratinization.
    Bovenschen HJ; Erceg A; Van Vlijmen-Willems I; Van De Kerkhof PC; Seyger MM
    J Dermatolog Treat; 2007; 18(1):32-9. PubMed ID: 17365265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation.
    Bovenschen HJ; Seyger MM; Van de Kerkhof PC
    Br J Dermatol; 2005 Jul; 153(1):72-8. PubMed ID: 16029329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with fumaric acid esters in an 11-year-old male child with psoriasis.
    Gerdes S; Domm S; Mrowietz U
    Dermatology; 2011; 222(3):198-200. PubMed ID: 21502753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microdialysis documents changes in the micromilieu of psoriatic plaques under continuous systemic therapy.
    Salgo R; Thaçi D; Boehncke S; Diehl S; Hofmann M; Boehncke WH
    Exp Dermatol; 2011 Feb; 20(2):130-3. PubMed ID: 21255092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dimethylfumarate for psoriasis: Pronounced effects on lesional T-cell subsets, epidermal proliferation and differentiation, but not on natural killer T cells in immunohistochemical study.
    Bovenschen HJ; Langewouters AM; van de Kerkhof PC
    Am J Clin Dermatol; 2010; 11(5):343-50. PubMed ID: 20553063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphopenia and CD4+/CD8+ Cell Reduction under Fumaric Acid Esters.
    Sondermann W; Rompoti N; Leister L; Huptas L; Klode J; Dissemond J; Körber A
    Dermatology; 2017; 233(4):295-302. PubMed ID: 28954274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fumaric acid esters.
    Rostami Yazdi M; Mrowietz U
    Clin Dermatol; 2008; 26(5):522-6. PubMed ID: 18755371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of fumaric acid esters and dithranol on acanthosis and hyperproliferation in psoriasis vulgaris.
    Bacharaçh-Buhles M; Röchling A; el Gammal S; Altmeyer P
    Acta Derm Venereol; 1996 May; 76(3):190-3. PubMed ID: 8800297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic antipsoriatic combination therapy with fumaric acid esters for plaque-type psoriasis: report on 17 cases.
    Wilsmann-Theis D; Frambach Y; Philipp S; Weyergraf AJ; Jacobi A; Mössner R; Gerdes S
    Dermatology; 2015; 230(2):119-27. PubMed ID: 25661583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nail psoriasis improvement in a patient treated with fumaric acid esters.
    Vlachou C; Berth-Jones J
    J Dermatolog Treat; 2007; 18(3):175-7. PubMed ID: 17538807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fumaric acid esters in psoriasis and multiple sclerosis.
    Zecca C; Caporro M; Adami M; Mainetti C; Gobbi C
    Clin Exp Dermatol; 2014 Jun; 39(4):488-91. PubMed ID: 24779791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fumaric acid and its derivatives in the treatment of psoriasis vulgaris: our experience in forty-one patients.
    Kokelj F; Plozzer C; Avian A; Trevisan G
    Acta Dermatovenerol Croat; 2009; 17(3):170-5. PubMed ID: 19818215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.
    Goedkoop AY; Kraan MC; Teunissen MB; Picavet DI; de Rie MA; Bos JD; Tak PP
    Ann Rheum Dis; 2004 Jul; 63(7):769-73. PubMed ID: 15194570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities.
    Balasubramaniam P; Stevenson O; Berth-Jones J
    Br J Dermatol; 2004 Apr; 150(4):741-6. PubMed ID: 15099371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of systemic cyclosporin A on interleukin-2 and epidermal growth factor receptor expression in psoriatic skin lesions.
    Horroccks A; Ormerod AD; Duncan JI; Thomson AW
    Clin Exp Immunol; 1989 Nov; 78(2):166-71. PubMed ID: 12412743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological changes in psoriasis patients under long-term treatment with fumaric acid esters: risk of Kaposi sarcoma occurrence?
    Philipp S; Kokolakis G; Hund M; Witte E; Witte K; Kunz S; Roewert HJ; Sterry W; Sabat R
    Eur J Dermatol; 2013; 23(3):339-43. PubMed ID: 23774790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer and natural killer-T cells in psoriasis.
    Cameron AL; Kirby B; Fei W; Griffiths CE
    Arch Dermatol Res; 2002 Nov; 294(8):363-9. PubMed ID: 12420105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Psoriasis therapy with fumaric acid and fumaric acid esters].
    Raab W
    Z Hautkr; 1984 May; 59(10):671-9. PubMed ID: 6741206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.